Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Roberta Fazio
Observed name:
R. Fazio
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Université Libre de Bruxelles,
Humanitas University,
Institut Jules Bordet,
Erasmus Hospital,
Boston Scientific (United States),
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS Humanitas Research Hospital
show all 7
ORCID:
0009-0000-6690-2101
Observed ORCID:
0009-0000-6690-2101
OpenAlex ID:
A5017268001
Neoadjuvant chemotherapy for early-stage colon cancer
2023
·
Alessandro Audisio
, Roberta Fazio
, et al.
·
Cancer Treatment Reviews
·
68
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
2025
·
Alessandro Audisio
, Chiara Gallio
, et al.
·
JAMA Oncology
·
36
PDF
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
2023
·
Valentina Daprà
, Marco Airoldi
, et al.
·
International Journal of Molecular Sciences
·
35
PDF
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study
2021
·
Alessandro Pizzocaro
, Paolo Colombo
, et al.
·
Endocrine
·
24
PDF
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
2025
·
Alessandra Raimondi
, Gabriele Tinè
, et al.
·
Journal of Clinical Oncology
·
20
PDF
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
2024
·
Erika Stucchi
, Michela Bartolini
, et al.
·
Expert Opinion on Pharmacotherapy
·
20
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs
2024
·
Matteo Perrino
, Emanuele Voulaz
, et al.
·
Frontiers in Immunology
·
18
PDF
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study
2026
·
Veronica Conca
, Daniele Rossini
, et al.
·
Journal of Clinical Oncology
·
16
PDF
Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy
2023
·
Matteo Perrino
, Nadia Cordua
, et al.
·
Cancers
·
16
PDF
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
2024
·
Marco Airoldi
, Michela Bartolini
, et al.
·
Current Oncology Reports
·
8
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
2024
·
Roberta Fazio
, Alessandro Audisio
, et al.
·
Cancer Treatment Reviews
·
7
Advances in drug treatments for mesothelioma
2022
·
Paolo Andrea Zucali
, Fabio De Vincenzo
, et al.
·
Expert Opinion on Pharmacotherapy
·
7
Clinical trials for older cancer patients: A systematic review
2025
·
Roberta Fazio
, Alessandro Audisio
, et al.
·
Cancer Treatment Reviews
·
6
Abstract CT230: STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI
2026
·
Alberto Giovanni Leone
, Alessandra Raimondi
, et al.
·
Cancer Research
·
4
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial
2025
·
Paolo Manca
, Marta Paoli
, et al.
·
Clinical Cancer Research
·
3
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
2025
·
Carlotta Antoniotti
, Federica Marmorino
, et al.
·
European Journal of Cancer
·
3
PD-L1 Expression in Paired Samples of Rectal Cancer
2024
·
Mina Coussement
, Roberta Fazio
, et al.
·
Cancers
·
3
Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back?
2023
·
Alessandro Audisio
, Roberta Fazio
, et al.
·
Current Opinion in Oncology
·
3
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
2023
·
Maria Susanna Grimaudo
, Alice Laffi
, et al.
·
Frontiers in Oncology
·
3
PDF
Geometrical and electrical predictors of cardiac resynchronization therapy response
2014
·
Giuseppe Stabile
, Assunta Iuliano
, et al.
·
Expert Review of Cardiovascular Therapy
·
3
2141P Real world-data on neoadjuvant/definitive immunotherapy (IO) or chemo-immunotherapy (CT-IO) in patients (pts) with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) resectable or potentially resectable gastric/gastroesophageal junction (GEJ) carcinoma
2025
·
R. Fazio
, G. Di Liberti
, et al.
·
Annals of Oncology
·
2
Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis
2024
·
Daniel Sur
, Constantin Ionut Coroama
, et al.
·
Journal of Personalized Medicine
·
2
Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis
2026
·
A. Raimondi
, G. Tinè
, et al.
·
ESMO Open
·
1
PDF
Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025
2026
·
R. Fazio
, M. Ambrosini
, et al.
·
ESMO Gastrointestinal Oncology
·
1
The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.
2025
·
Andrea Pretta
, Francesca Bergamo
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
52
Citation count:
313
H-index:
9
I10-index:
9
Year
Topic
Type